Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.59 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931394 | 1.00 | TMPRSS2 (0.59) | TMPRSS2EGLN2NPC1ALDH1A1ATM | |
| SCHEMBL25909451 | 0.94 | TMPRSS2 (0.54) | TMPRSS2EGLN2NPC1ALDH1A1ATM | |
| SCHEMBL30931405 | 0.88 | TMPRSS2 (0.49) | TMPRSS2EGLN2 | |
| SCHEMBL24917399 | 0.88 | TMPRSS2 (0.49) | TMPRSS2EGLN2 | |
| SCHEMBL24790557 | 0.88 | TMPRSS2 (0.52) | TMPRSS2 | |
| SCHEMBL25909928 | 0.88 | TMPRSS2 (0.48) | TMPRSS2EGLN2ALDH1A1POLB | |
| SCHEMBL30931380 | 0.87 | TMPRSS2 (0.48) | TMPRSS2EGLN2 | |
| SCHEMBL30090991 | 0.87 | TMPRSS2 (0.48) | TMPRSS2EGLN2 | |
| SCHEMBL24791785 | 0.85 | TMPRSS2 (0.79) | TMPRSS2EGLN2NPC1ALDH1A1ATM | |
| SCHEMBL30931389 | 0.85 | TMPRSS2 (0.49) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885EGLN2 2347/4885NPC1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.